Tesamorelin / CJC-1295 / Ipamorelin – 12mg / 6mg / 6mg

$225.00

Tesamorelin / CJC-1295 / Ipamorelin (12 mg / 6 mg / 6 mg) is a research-grade peptide blend studied for its role in supporting growth hormone signaling and metabolic regulation. This formulation is designed to help promote healthy growth hormone activity, support cellular recovery processes, and maintain balanced metabolic function. The combination of these peptides is researched for its potential influence on pathways related to body composition, energy metabolism, and tissue repair, making it a compound of interest for studies focused on metabolic optimization, physical performance, and overall cellular health.

The Tesamorelin / CJC-1295 / Ipamorelin (12mg / 6mg / 6mg) triple-peptide blend is a premier research configuration designed to explore maximum growth hormone (GH) secretagogue synergy. By combining two distinct GHRH receptor agonists with a highly selective GHRP pentapeptide, this formulation serves as an advanced investigative tool for tracking accelerated visceral lipolysis, lean tissue repair, and metabolic efficiency in laboratory models.

Supplied as a stable, high-purity lyophilized powder blend in a single 24mg total mass vial. Restricted strictly to laboratory and in vitro research applications.

Description

Eterna Peptides presents a premium, high-purity triple blend of Tesamorelin (12mg), CJC-1295 No DAC (6mg), and Ipamorelin (6mg) lyophilized powder. This advanced formulation combines three distinct growth hormone secretagogues to study multi-pathway synergy, metabolic regulation, and cellular tissue repair.

Mechanism of Action
This specialized research blend leverages two unique pathways to optimize growth hormone ($GH$) signaling pathways without triggering systemic desensitization:
* **Tesamorelin (GHRH Analog):** A synthetic peptide containing all 44 amino acids of human GHRH with an added trans-3-hexenoic acid group. Research demonstrates its specific affinity for targeting and regulating visceral adipose tissue metabolism and reducing lipodystrophy markers.
* **CJC-1295 No DAC (Modified GHRH 1-29):** Acts as a shortened, highly stable GHRH receptor agonist. It works closely with Tesamorelin to sustain pulsatile growth hormone synthesis and protect against rapid enzymatic ($DPP-IV$) degradation.
* **Ipamorelin (Selective GHRP):** A potent pentapeptide that binds selectively to the Growth Hormone Secretagogue Receptor ($GHSR$) in the pituitary gland. It stimulates a clean pulse of endogenous GH release without elevating cortisol, prolactin, or aldosterone levels.

Research Applications
In preclinical and in vitro research settings, this triple-blend configuration is heavily evaluated to study:
* Accelerated adipose tissue lipolysis, specifically targeting visceral (deep abdominal) fat depots.
* Enhanced lean muscle mass development, skeletal repair, and localized protein synthesis cascades.
* Advanced cellular repair, tissue rejuvenation, and structural collagen density optimization.
* The synergistic dynamics of combining multi-receptor GHRH and GHRP secretagogues to maximize cellular saturation.

Our triple-blend vials undergo stringent laboratory validation to guarantee perfect compound ratios, maximum structural purity, and exceptional analytical consistency across all experimental models.


*Disclaimer: This product is sold strictly for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic purposes.*

Menu

Research Categories